The reason for this study is to see if the study drug baricitinib given orally is safe and effective in participants with JIA from 2 years to less than 18 years old.
| Condition | Autoimmune disease, JUVENILE RHEUMATOID ARTHRITIS, Arthritis, Arthritis and Arthritic Pain, Arthritis and Arthritic Pain (Pediatric), juvenile idiopathic arthritis |
|---|---|
| Treatment | Placebo, Baricitinib |
| Clinical Study Identifier | NCT03773978 |
| Sponsor | Eli Lilly and Company |
| Last Modified on | 14 April 2021 |
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer
Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!
No annotations made yet
Congrats! You have your own personal workspace now.